Morningstar2d
Prometheus Laboratories Launches New Anser(R) Test for Risankizumab
1 Additionally, development of antibodies to risankizumab has been associated with lower RZB concentrations, reduced clinical response, hypersensitivity and infusion site reactions.2 "Prometheus ...
Dermatology Advisor8d
Risankizumab May Be Superior to Other Biologic Therapies in Plaque Psoriasis
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Medical Dialogues7d
Risankizumab improves long-term outcomes in patients with palmoplantar pustulosis: Study
A new study published in The Journal of Dermatology revealed that patients with palmoplantar pustulosis (PPP) who were 18 ...
Healio9d
Extended treatment with Skyrizi ‘may ultimately benefit’ refractory Crohn’s disease
Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...
Medscape14d
Anti–IL-23 Therapy Might Emerge as Best Biologic in Psoriasis if Used Early and at High Doses
In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...
pharmaphorum8d
AbbVie to file long-acting psoriasis contender
AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor ...
MedPage Today13d
Risankizumab Makes a Difference in Hard-to-Treat Psoriasis
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The IL-23 inhibitor risankizumab proved to be safe and efficacious after 52 weeks of treatment in patients with ...
Prometheus Laboratories Launches New Anser Test for Risankizumab
Inhibitor SAN DIEGO, CA / ACCESS Newswire / April 1, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision-guided medicine, announces ...